

PHENACETIN (Group 2A) and ANALGESIC MIXTURES CONTAINING PHENACETIN (Group 1)

A. Evidence for carcinogenicity to humans (*limited* for phenacetin; *sufficient* for analgesic mixtures containing phenacetin)

There have been many case reports of renal pelvic and other urothelial tumours in patients who had used large amounts of phenacetin-containing analgesics¹⁻¹³. Case-control studies have been consistent in showing a positive association between cancer of the renal pelvis and cancer of the bladder and use of phenacetin-containing analgesics, with relative risks varying from 2.4 to over 6; these associations have not been explained by confounding with other causes of urothelial cancer, and, where looked for, a positive dose-response relationship has been evident¹⁴⁻¹⁹. In one study¹⁴, use of nonphenacetin-containing analgesics appeared to increase the risk of cancer of the renal pelvis to the same extent as did phenacetin-containing analgesics. This result was not obtained in other studies^{15,17,18}.

B. Evidence for carcinogenicity to animals (*sufficient* for phenacetin; *limited* for analgesic mixtures containing phenacetin)

Phenacetin given orally induced benign and malignant tumours of the urinary tract in mice²⁰ and rats^{1,21} and of the nasal cavity in rats¹. When given in combination with aspirin and caffeine to rats or mice, no significant association was found with the incidence of tumours¹. In rats, phenacetin alone or in combination with phenazone slightly increased the incidences of renal-cell and renal-pelvic tumours; rats treated with phenacetin, phenazone and caffeine in combination developed hepatomas²². Also in rats, phenacetin enhanced the incidence of urinary bladder tumours induced by *N*-nitrosobutyl-*N*-(4-hydroxybutyl)-amine¹, and prevented the induction of hepatocellular carcinomas by 2-acetylaminofluorene²³.

C. Other relevant data

No data were available on the genetic and related effects of phenacetin in humans.

The results of studies on the induction of chromosomal aberrations, sister chromatid exchanges and micronuclei in rodents treated with phenacetin *in vivo* were equivocal. Phenacetin induced chromosomal aberrations in Chinese hamster cells *in vitro* but not DNA strand breaks in rat hepatocytes. It did not induce sex-linked recessive lethal mutations in *Drosophila*. Phenacetin was mutagenic to bacteria when tested in the presence

of a metabolic system derived from hamster but not mouse or rat liver. The urine from phenacetin-treated Chinese hamsters, but not that from rats, was mutagenic to bacteria²⁴.

References

- ¹IARC *Monographs*, 24, 135-161, 1980
- ²Christensen, T.E. & Ladefoged, J. (1979) Carcinomata in the urinary tract in patients with contracted kidneys and massive abuse of analgesics (phenacetin) (Dan.). *Ugeskr. Laeg.*, 141, 3522-3524
- ³Gonwa, T.A., Corbett, W.T., Schey, H.M. & Buckalew, V.M., Jr (1980) Analgesic-associated nephropathy and transitional cell carcinoma of the urinary tract. *Ann. intern. Med.*, 93, 249-252
- ⁴Mihatsch, M.J., Manz, T., Knüsli, C., Hofer, H.O., Rist, M., Guetg, R., Rutishauser, G. & Zollinger, H.U. (1980) Phenacetin abuse. III. Malignant urinary tract tumours with phenacetin abuse in Basel, 1963-1977 (Ger.). *Schweiz. med. Wochenschr.*, 110, 255-264
- ⁵Orell, S.R., Nanra, R.S. & Ferguson, N.W. (1979) Renal pelvic carcinoma in the Hunter Valley. *Med. J. Aust.*, 524, 555-557
- ⁶Blohmé, I. & Johansson, S. (1981) Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy. *Kidney int.*, 20, 671-675
- ⁷Syré, G. & Matejka, M. (1981) Phenacetin abuse and renal pelvis carcinomas (Ger.). *Wien. klin. Wochenschr.*, 93, 420-423
- ⁸Porpáczy, P. & Schramek, P. (1981) Analgesic nephropathy and phenacetin-induced transitional cell carcinoma — analysis of 300 patients with long-term consumption of phenacetin-containing drugs. *Eur. Urol.*, 7, 349-354
- ⁹Mihatsch, M.J., Brunner, F.P., Korteweg, E., Rist, M., Dalquen, P. & Thiel, G. (1982) Phenacetin abuse. VII. Tumours of the urinary tract in haemodialysis and kidney transplant patients (Ger.). *Schweiz. med. Wochenschr.*, 112, 1468-1472
- ¹⁰Novák, J. & Žídek, I. (1983) Phenacetin as a carcinogen for the renal pelvis (Czech.). *Čas. Lék. čes.*, 122, 1149-1152
- ¹¹Mihatsch, M.J. & Knüsli, C. (1982) Phenacetin abuse and malignant tumors. An autopsy study covering 25 years (1953-1977). *Klin. Wochenschr.*, 60, 1339-1349
- ¹²Marek, J. & Hradec, E. (1985) Chronic sclerosing ureteritis and nephrogenic adenoma of the ureter in analgesic abuse. *Pathol. Res. Pract.*, 180, 569-573
- ¹³Kliment, J. (1979) Renal pelvis tumours and abuse of analgesics (Czech.). *Bratisl. lék. Listy*, 72, 641-764
- ¹⁴McCredie, M., Ford, J.M., Taylor, J.S. & Stewart, J.H. (1982) Analgesics and cancer of the renal pelvis in New South Wales. *Cancer*, 49, 2617-2625
- ¹⁵McCredie, M., Stewart, J.H., Ford, J.M. & MacLennan, R.A. (1983) Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. *Br. J. Urol.*, 55, 220-224
- ¹⁶McCredie, M., Stewart, J.H. & Ford, J.M. (1983) Analgesics and tobacco as risk factors for cancer of the ureter and renal pelvis. *J. Urol.*, 130, 28-30
- ¹⁷McLaughlin, J.K., Mandel, J.S., Blot, W.J., Schuman, L.M., Mehl, E.S. & Fraumeni, J.F., Jr (1984) A population-based case-control study of renal cell carcinoma. *J. natl Cancer Inst.*, 72, 275-284
- ¹⁸Piper, J.M., Tonascia, J. & Matanoski, G.M. (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. *New Engl. J. Med.*, 313, 292-295

- ¹⁹Piper, J.M., Matanoski, G.M. & Tonascia, J. (1986) Bladder cancer in young women. *Am. J. Epidemiol.*, 123, 1033-1042
- ²⁰Nakanishi, K., Kurata, Y., Oshima, M., Fukushima, S. & Ito, N. (1982) Carcinogenicity of phenacetin: long-term feeding study in B6C3F₁ mice. *Int. J. Cancer*, 29, 439-444
- ²¹Muradyan, R.Y. (1986) Experimental studies of phenacetin carcinogenicity (Russ.). *Vopr. Onkol.*, 32, 63-70
- ²²Johansson, S.L. (1981) Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). *Int. J. Cancer*, 27, 521-529
- ²³Yamamoto, R.S., Frankel, H.H. & Weisburger, E.K. (1979) Effect of phenacetin and *N*-alkylacetanilides on *N*-2-fluorenylacetamide hepatocarcinogenesis. *Cancer Lett.*, 8, 183-188
- ²⁴*IARC Monographs, Suppl. 6*, 448-450, 1987